TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05999084

Intervention type: DRUG
Intervention: Anti-amyloid Monoclonal Antibodies (mAbs)
Description: Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.

Intervention type: DRUG
Intervention: Anti-amyloid Monoclonal Antibodies (mAbs)
Description: Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.

Intervention type: COMBINATION_PRODUCT
Intervention: Standard of Care
Description: The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.
Study: NCT06505408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: 4 capsules of Perelel Health Conception Support Multivitamin Pack (consisting of vitamins, minerals, and omega ingredients) consumed daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo capsules consumed daily for 12 weeks
Study: NCT05347693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local standard of care
Description: Local SoC in the country to be used as per local label
Study: NCT06574880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-PSMA-617
Description: Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule:~* Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT.~* Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2.~* Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Description: Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).
Study: NCT06445556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NatureUplift
Description: a culturally tailored, nature-based program offered at the TRPD. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing). Following week 12, participant dyads who were randomized to the NatureUplift intervention (i.e., delayed intervention arm) will receive access to 4 additional weeks of the NatureUplift+Active intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NatureUplift+Active
Description: NatureUplift plus a supplementary walking/hiking educational component. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing) prescribed during the NatureUplift condition and an additional 60 min/week of supplementary moderate- intensity activities (e.g., walking and hiking) prescribed during the NatureUplift+Active condition. Those who were randomized to the NatureUplift+Active intervention will continue to receive access to 4 additional weeks of the NatureUplift+Active intervention.
Study: NCT02137525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 6 mg
Description: Intravenous infusion - delivering morphine 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 µg
Description: Fentanyl sublingual spray - single unit delivering 100 µg fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 200 µg
Description: Fentanyl sublingual spray - single unit delivering 200 µg fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 400 µg
Description: Fentanyl sublingual spray - single unit delivering 400 µg fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Sublingual Spray
Description: Matching sublingual spray - single unit delivering 0 µg fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Matching intravenous infusion - delivering 0 mg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Matching intravenous infusion - delivering 0 mg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Matching intravenous infusion - delivering 0 mg morphine
Study: NCT06646029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMO flexion orthosis (splint)
Description: RMO flexion is an orthosis fabricated by hand therapists made of thermoplastic material design to position the involved finger in relative flexion at the metacarpal joint compared to adjacent fingers to facilitate PIP extension during daily activity use.
Study: NCT05658367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with sesame- lavender oil mixed
Description: After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy massage with sesame oil
Description: After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Massage with parraffin oil
Description: After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
Study: NCT05612386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study: NCT05822596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-based interactive games experimental group intervention
Description: The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes
Study: NCT05420428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic airway device
Description: under general anesthesia, patients received supraglottic airway device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: endotracheal intubation
Description: under general anesthesia, patients received endotracheal intubation
Study: NCT05488132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-siglec-6 CAR-T cell therapy
Description: Enrolled patients will receive prespecified dose of autologous CAR-T cells.
Study: NCT05521854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare app (app-based contingency management)
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare app (app-based contingency management)
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare app (app-based contingency management)
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare app (app-based contingency management)
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare app (app-based contingency management)
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare app (app-based contingency management)
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Participants get access to the DynamiCare app but will not be provided with financial incentives.
Study: NCT06020612

Intervention type: OTHER
Intervention: Assessment by dermatopathologists
Description: Histological assessment of the cSCCs by eight dermatopathologists.
Study: NCT05059379

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Entire supraclavicular lymph node radiotherapy
Description: Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Medial supraclavicular lymph node radiotherapy
Description: Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
Study: NCT04436315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor-cognitive training device
Description: Motor-cognitive training device

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Active control condition
Description: Physical activity program
Study: NCT05847179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progerinin
Description: This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.
Study: NCT06075420

Intervention type: DEVICE
Intervention: Genoss DES stent
Description: The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Study: NCT05547243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
Description: 50μg/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine, Bivalent High dose
Description: 100μg/dose
Study: NCT05721742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtually administered dietitian consults for IBS patients.
Description: Participants will receive virtual one on one consults with a dietitian who has training in the dietary management of IBS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IBS Group Online Session
Description: IBS online group session run by Happy Bellies Nutrition
Study: NCT05978544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab
Description: Patients to be treated with Itolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab
Description: Patients to be treated with Itolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab
Description: Patients to be treated with Itolizumab.
Study: NCT06285851

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeSC
Description: Supplement
Study: NCT06075446

Intervention type: BEHAVIORAL
Intervention: ACT Raising Safe Kids
Description: American Psychological Association ACT Raising Safe Kids
Study: NCT05547243

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT05114655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbaceous Essential Oil Blend
Description: Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.
Study: NCT06646029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Treatment includes finger stretches, active range of motion (AROM), passive range of motion (PROM), thermal modalities, LMB finger extension orthosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Treatment includes finger stretches, active range of motion (AROM), passive range of motion (PROM), thermal modalities, LMB finger extension orthosis.
Study: NCT04074304

Intervention type: OTHER
Group type: OTHER
Intervention: I-HoME
Description: A multi-component technology-based care intervention.
Study: NCT05114655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus Essential Oil Blend
Description: Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Oil
Description: Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
Study: NCT05158296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultevursen
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultevursen
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-procedure
Description: Sham-procedure (no experimental drug administered)
Study: NCT04752449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Cognitive Behavioural Therapy for Psychosis
Description: CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
Study: NCT05037968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagnetOs Flex Matrix
Description: Procedure: Instrumented Posterolateral Lumbar Fusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trinity Elite
Description: Procedure: Instrumented Posterolateral Lumbar Fusion
Study: NCT00269802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06408610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity continuous training
Description: exercise and diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity continuous training
Description: exercise and diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity continuous training
Description: exercise and diet
Study: NCT04728048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural puncture epidural
Description: already described

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard epidural
Description: already described
Study: NCT05666219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline Injection
Description: Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
Study: NCT05093049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renuvion APR System
Description: The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gynecomastia Correction Surgery
Description: Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gynecomastia Correction Surgery
Description: Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
Study: NCT06380699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD106 Injection
Description: PEG-tissue kallikrein-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD106 Injection
Description: PEG-tissue kallikrein-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Urinary Kallidinogenase
Description: tissue kallikrein-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04858698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound / Echocardiography
Description: Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound / Echocardiography
Description: Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
Study: NCT06148220

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
Description: Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
Description: Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
Study: NCT05081869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Education Program
Description: There will be video training on the subject for both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program
Description: There will be video training on the subject for both groups.
Study: NCT06081764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
Study: NCT05771909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeurodigitX
Description: The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day).

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The Control Group does not receive the NeurodigitX application.
Study: NCT05369715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise
Study: NCT05906082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette cessation text-messaging intervention
Description: This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.